Questions?arveonix@protonmail.com•Telegram @arveonix

Last updated:

ARVEONIX Retatrutide 10mg research product box and vial
Metabolic research · SKU RT10

Retatrutide 10mg

$85.00 AUD
In stock
Free shipping Australia-wideOrders over $150

Retatrutide is an investigational triple GLP-1, GIP and glucagon receptor agonist studied in metabolic and multi-receptor signalling research.

ProductRetatrutide 10mg
SKURT10
CategoryMetabolic research
Listed price$85.00 AUD
AvailabilityIn stock
Confirm current availability when making an enquiry.

What is Retatrutide?

Retatrutide is an investigational peptide engineered for activity at three receptor systems involved in metabolic signalling: GLP-1R, GIPR and the glucagon receptor. Its triple-agonist design is an important area of research in next-generation incretin pharmacology.

Laboratory and clinical research examines how combined receptor engagement influences endocrine and metabolic pathways. The 10mg ARVEONIX catalogue listing represents the lower of the two Retatrutide strengths currently shown on the site.

Research category

Metabolic research

ARVEONIX format

Retatrutide 10mg · SKU RT10

Primary research context

GLP-1, GIP and glucagon receptor research

Catalogue status

In stock · $85.00 AUD

GLP-1, GIP and glucagon receptor research.

The three receptor systems targeted by Retatrutide have distinct but interacting roles in metabolic physiology. Studying them together can provide insight into how multi-agonist molecules alter signalling compared with more selective compounds.

Research interpretation should consider receptor potency, exposure, study duration and the population or experimental model being assessed.

Common research themes.

Triple agonism

Research into coordinated activity across three metabolic receptors.

Incretin biology

Study of GLP-1 and GIP receptor pathways.

Glucagon signalling

Investigation of GCGR activity within a multi-agonist profile.

Comparative pharmacology

Comparison with dual agonists such as Tirzepatide.

How Retatrutide, Tirzepatide, Semaglutide and Liraglutide differ.

These molecules are often grouped together because they all involve GLP-1 receptor signalling, but their receptor profiles are not the same. The main pharmacological distinction is whether the molecule targets GLP-1 alone or combines GLP-1 activity with additional metabolic receptor pathways.

The comparison below describes receptor targets and development status rather than ranking efficacy, safety or suitability. Approved branded medicines and ARVEONIX research catalogue products should not be treated as interchangeable formulations.

Molecule Receptor targets Agonist profile Current research / regulatory context
Liraglutide GLP-1 receptor Single GLP-1 receptor agonist Established GLP-1 medicine with approved therapeutic formulations.
Semaglutide GLP-1 receptor Single GLP-1 receptor agonist Established GLP-1 medicine with approved therapeutic formulations.
Tirzepatide GIP + GLP-1 receptors Dual incretin receptor agonist Approved dual GIP/GLP-1 therapeutic molecule in regulated formulations.
Retatrutide GIP + GLP-1 + glucagon receptors Triple receptor agonist Investigational molecule in Phase 3 development; not yet approved for public therapeutic use.

In simplified terms, the progression is from single-receptor GLP-1 agonism with liraglutide and semaglutide, to dual GIP/GLP-1 agonism with Tirzepatide, and then to triple GIP/GLP-1/glucagon agonism with Retatrutide. More receptor targets do not, by themselves, establish that one compound is superior to another.

Research considerations.

Research findings should always be interpreted within the experimental system in which they were produced. Cell, receptor, tissue, animal and human studies can answer different questions, and results from one model should not automatically be treated as established outcomes in another.

ARVEONIX product pages therefore focus on molecule identity, pathway biology and published research themes rather than presenting experimental observations as guaranteed effects. The information here is not a dosing, treatment or individual-use recommendation.

Retatrutide FAQs.

What receptors does Retatrutide target?

Retatrutide is designed to activate GLP-1, GIP and glucagon receptors.

Is Retatrutide a GLP-1-only compound?

No. Its research profile includes three receptor systems rather than GLP-1 alone.

How does Retatrutide differ from Tirzepatide?

Retatrutide adds glucagon-receptor activity to the GIP/GLP-1 receptor combination targeted by Tirzepatide.

What does investigational mean?

It means the compound is still being studied and research findings should not be presented as established general outcomes.

What strength is listed here?

This ARVEONIX catalogue page lists Retatrutide 10mg under SKU RT10.

What research themes are associated with Retatrutide?

Metabolic signalling, incretin biology, receptor pharmacology and multi-agonist design.

Does this page recommend individual use?

No.